|
MRI News Service:
'Phase' p2 |
|
|
|
 |
 | | | ''A medical imaging solution tailored to the particular requirements of early-phase clinical trials has been launched by ICON, the outsourced development-services provider based in Ireland. There is a growing trend of using Positron emission tomography ...' | | Thursday, 18 October 2012 by www.pharmatimes.com |
|
|
|
| | | ''The purpose of this prospective study was to evaluate the accuracy of in-phase and out-of-phase imaging to assess hepatic iron concentration in patients with haematological malignancies and chronic liver disease. MRI-based hepatic iron concentration ...' | | | Friday, 1 June 2012 by www.ncbi.nlm.nih.gov | |
|
|
|
| | | ''Developing drugs to combat or cure human disease often involves a phase of testing with mice, so being able to peer clearly into a living mouse's innards has real value. But with the fluorescent dyes currently used to image the interior of laboratory ...' | | | Friday, 27 May 2011 by www.eurekalert.org | |
|
|
|
| | | ''Repligen Corporation (NASDAQ: RGEN) reported today positive top-line results from a Phase 3 study to evaluate the safety and efficacy of RG1068, synthetic human secretin, to improve magnetic resonance imaging (MRI) of the pancreas in patients with ...' | | | Monday, 14 March 2011 by www.businesswire.com | |
|
|
|
| | | ''Phase-contrast magnetic resonance imaging (PC-MRI) enables quantification of cerebrospinal fluid (CSF) flow and total cerebral blood (tCBF) flow and may be of value for the etiological diagnosis of neurodegenerative diseases. This investigation aimed to ...' | | | Wednesday, 16 February 2011 by 7thspace.com | |
|
|
|
| | | ''Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of SIMPONI® (golimumab) 50 mg plus methotrexate resulted in statistically significant improvements in markers of ...' | | | Monday, 8 November 2010 by www.prnewswire.com | |
|
|
|
| | | ''Downstaging locally advanced rectal cancer with capecitabine and oxaliplatin prior to surgery and chemoradiotherapy may improve survival, a phase II trial suggests. In the January 26 online issue of The Lancet Oncology, authors suggest that ...' | | | Tuesday, 26 January 2010 by www.curetoday.com | |
|
|
|
| | | ''Repligen Corporation (Nasdaq: RGEN) reported today that it has completed patient treatment in its Phase 3 clinical trial of RG1068, synthetic human secretin, in magnetic resonance imaging (MRI) of the pancreas. The study is designed to assess the ...' | | | Monday, 19 October 2009 by au.sys-con.com | |
|
|
|
| | | ''Genomas(R), a biomedical company advancing DNA-Guided medicine, today announced the award of a 3-year Phase II Small Business Innovation Research (SBIR) Grant totaling $1.4 Million. The grant, entitled MRI DNA Biomarkers for Neuropsychiatric Disease, ...' | | | Tuesday, 15 September 2009 by www.biospace.com | |
|
|
|
| | | ''After two years of intensive work the results from the German pilot phase of the EuroCMR Register are due to be published in the forthcoming issue of the Journal of the American College of Cardiology, and also presented and discussed in detail at this ...' | | | Wednesday, 19 August 2009 by www.european-hospital.com | |
|
|
|
|
|
|
|
|
| Result Pages |
|
|
|
|
|
Excess on occasion is exhilarating. It prevents moderation from acquiring
the deadening effect of a habit.
- W. Somerset Maugham |
|
|
News
top
